1993 Fiscal Year Final Research Report Summary
Seroepidemiological studies on hepatitis E and development of vaccine.
Grant-in-Aid for international Scientific Research
|Allocation Type||Single-year Grants |
|Research Institution||Nihon University |
SHIKATA Toshio Nihon Univ., Medicine Professor -> 日本大学, 医学部, 教授 (50009932)
AYE Thein Thein B.M.R.
SHROSTHA S.M. Bir Hospital, 内科部長
荘 輝 北京医科大学, 医学部, 教授
INABA Yutaka Juntendo Univ., Medicine Professor, 医学部, 教授 (30010094)
SUGITANI Masahiko Nihon Univ., Medicine Lecturer, 医学部, 講師 (40187654)
ESUMI Mariko Nihon Univ., Medicine Associate Professor, 医学部, 助教授 (60160363)
UCHIDA Toshikazu Nihon Univ., Medicine Associate Professor, 医学部, 助教授 (80060078)
HUI Zhuang Beijing Medical College Professor
|Project Period (FY)
1991 – 1993
|Keywords||Hepatitis E / Virus genome / Animal model / Vaccine / anti-HEV|
Hepatitis E is similer to hepatitis A. Hepatitis E virus (HEV) is transmitted by fecal-oral route and only cause acute hepatitis. This hepatitis E is mainly observed in South-Asia, such as India, Nepal, Myanmar, Uiguru Autonomous Region of China. Attempt was made to 1. establish an animal model, 2. identify a causative virus, 3. molecular clone of HEV genomne, 4. establish an assay kit for diagnosis and sero-epidemiological study of hepatitis E. 5. Vaccine development.
If we inoculate enough amount virus intravenously into rhesus monkeys we could produce acute hepatitis in animals. Also we could get large amount virus from the bile of the infected animals. We constructed lambda gt11 cDNA library from the bile and immunoscreened HEVRNA. We got 4 clones from 3'terminal and finally we sequenced whole genome of HEV. We also compared sequence of Burmese clone and Chinese clone. Homology was 93% in nucleic acid. We established assay kit for anti-HEV using peptide of 3'terminal region. We screened acute sporadic hepatitis in Japan, China and Miyanmar. We found in Japan, we observed very few imported cases of hepatitis E. However, in China, even Beijing and Shanghai, almost 10% of acute sporadic hepatitis cases were caused by HEV. We did efficacy experiment of recombinant vaccine using monkeys. However, we failed to protect HEV infection by our vaccine.
Research Products (2 results)